## Technology Brief: Genetic Signature for the Identification of Metastatic Melanoma

Docket Number: 06B073

### Summary
- Gene expression analyzed in 250 primary and metastatic melanomas procured at the time of surgical resection
- Approximately 1,000 genes identified to be differentially expressed in the transition from primary to metastatic melanoma
- A subset of 60 genes for which differential expression is associated with metastatic potential and tumor thickness

### Features and Benefits
- Can aid in the pathology determination of tumor when histology or morphology are inconclusive
- Distinguish between new primary tumors or metastasized tumors from a different primary source
- Adaptable to gene chip or related diagnostic devices

### Stage of Development
The gene expression signature continues to be developed in an effort to minimize the number of genes needed for a diagnostic test for melanoma metastatic condition.

### Inventor
Dr. A. Riker and Dr. S.A. Enkemann

### Publication and Patent Status
- Utility patent application granted.

---

Contact: Ray Carpenter  
Sr. Intellectual Property Associate  
Office of Technology Management and Licensing  
H. Lee Moffitt Cancer Center and Research Institute  
12902 Magnolia Drive MRC-TTO  
Tampa, FL 33612  
Email: Ray.Carpenter@moffitt.org  
Telephone: 813-745-6902  
Website: [http://www.moffitt.org/OTMC](http://www.moffitt.org/OTMC)